Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal

Biotech Has At Least Eight Major Partners

 
• By Mandy Jackson
  
Skyhawk's lead in-house drug candidate is also for a neurological indication, Huntington's disease (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business